Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Technical Presentation (January 2019)

8 slides from Aerie Pharmaceuticals's technical presentation, Jan 4, 2019

  1. Slide 1: AR-13324-CS205 Clinical Pilot Study Topline Results

    AR-13324-CS205 Clinical Pilot Study Topline Results Exhibit 99.2

  2. Slide 2: Important Information

    Important Information The information in this presentation is current only as of its date and may have changed or may change in the future. We undertake no obligation to update this information in light of new information, future events or otherwise. We are not making any representation or warranty

  3. Slide 3: Executive Summary

    Executive Summary Netarsudil 0.02% and 0.04% were safe and generally well tolerated in Japanese-American subjects Netarsudil 0.02% and 0.04% were efficacious in lowering IOP in Japanese-American subjects Both concentrations appear to have similar efficacy, but need larger sample size before drawing

  4. Slide 4: AR-13324-CS205 Trial Design

    AR-13324-CS205 Trial Design Patients randomized 1:1:1 Primary endpoints: Safety: Ocular and systemic safety during a 4-week treatment period Efficacy: Mean diurnal IOP at Week 4 Patients (Japanese-American within second generation) with open angle glaucoma (OAG) with IOP (unmedicated) ≥ 15 mmHg and

  5. Slide 5: Efficacy – Mean Diurnal IOP

    Efficacy – Mean Diurnal IOP Note small sample sizes (N=12 to 14) Very different baseline IOPs for 0.02% vs 0.04%* Need to compare using change from baseline analyses *One (1) subject in Netarsudil 0.04% has a higher baseline IOP For Investor Use ++Data on File

  6. Slide 6: Efficacy – Change in Mean Diurnal IOP

    Efficacy – Change in Mean Diurnal IOP 0.02% efficacy stable at -5.0 to -5.3 mmHg 0.04% efficacy “bouncing around” but similar to 0.02% at Week 1 and Week 4 Placebo effect similar to other studies For Investor Use ++Data on File

  7. Slide 7: Safety/Tolerability Overview of Netarsudil

    Safety/Tolerability Overview of Netarsudil There were no serious adverse events (SAEs) The most common adverse event was conjunctival hyperemia and was scored as mild in the majority of the patients For Investor Use ++Data on File

  8. Slide 8: Mean Hyperemia Score Over Time at 8am

    Mean Hyperemia Score Over Time at 8am For Investor Use ++Data on File

Aerie Pharmaceuticals — Technical Presentation (January 2019) on 6ix